Dr. Jagannath received his medical training at Maharaja Sayajirao University in Baroda, India. He completed his residencies at the Bronx-Lebanon Hospital Center, New York, and Harper-Grace Hospital Wayne State University in Detroit. Dr. Jagannath continued his post-doctoral training with an oncology fellowship at UTSCC-MD Anderson Hospital and Tumor Institute in Houston. He is currently Director of the Multiple Myeloma Program, Mount Sinai Medical Center, and Professor of Medicine (hematology and medical oncology), Tisch Cancer Institute, Mount Sinai School of Medicine, New York.

Dr. Jagannath is an active member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology and a Project Review Committee member for the Multiple Myeloma Research Consortium. He has published extensively on topics concerning multiple myeloma and bone marrow transplantation, and is often an invited lecturer. He is editor-in-chief of Clinical Lymphoma & Myeloma and a peer reviewer for many other medical journals. Dr. Jagannath has received numerous awards in honor of his work related to the study and treatment of myeloma and is widely respected for his knowledge and accomplishments in bone marrow transplantation.

Dr. Jagannath is an active member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology and a Project Review Committee member for the Multiple Myeloma Research Consortium. He has published extensively on topics concerning multiple myeloma and bone marrow transplantation, and is often an invited lecturer. He is editor-in-chief of Clinical Lymphoma & Myeloma and a peer reviewer for many other medical journals. Dr. Jagannath has received numerous awards in honor of his work related to the study and treatment of myeloma and is widely respected for his knowledge and accomplishments in bone marrow transplantation.

During his years at MD Anderson Cancer Institute, he pioneered the role of high-dose therapy for Hodgkin’s disease that became the standard conditioning regimen for relapse. He was recruited to the University of Arkansas for Medical Sciences as chief of transplant to establish a transplant program that included autologous, allogeneic and matched unrelated transplants. During his tenure there, he made significant contributions towards stem cell purification, cyclophosphamide and growth factor as well as growth factor alone for the use in stem cell mobilization and tandem transplantation for multiple myeloma.

Faculty Disclosure
Dr. Sundar Jagannath has received grant support related to research activities from Celgene Corporation, Millennium Pharmaceuticals, Inc., and Novartis AG.